Viiv Hlthcare Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VIIV HLTHCARE, and when can generic versions of VIIV HLTHCARE drugs launch?
VIIV HLTHCARE has twenty-six approved drugs.
There are twelve US patents protecting VIIV HLTHCARE drugs.
There are five hundred and ten patent family members on VIIV HLTHCARE drugs in fifty-nine countries and two hundred and eleven supplementary protection certificates in eighteen countries.
Summary for Viiv Hlthcare
International Patents: | 510 |
US Patents: | 12 |
Tradenames: | 19 |
Ingredients: | 17 |
NDAs: | 26 |
Drugs and US Patents for Viiv Hlthcare
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viiv Hlthcare | TIVICAY | dolutegravir sodium | TABLET;ORAL | 204790-001 | Aug 12, 2013 | RX | Yes | Yes | 8,129,385*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Viiv Hlthcare | DOVATO | dolutegravir sodium; lamivudine | TABLET;ORAL | 211994-001 | Apr 8, 2019 | RX | Yes | Yes | 8,129,385*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Viiv Hlthcare | RUKOBIA | fostemsavir tromethamine | TABLET, EXTENDED RELEASE;ORAL | 212950-001 | Jul 2, 2020 | RX | Yes | Yes | 8,461,333 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Viiv Hlthcare | JULUCA | dolutegravir sodium; rilpivirine hydrochloride | TABLET;ORAL | 210192-001 | Nov 21, 2017 | RX | Yes | Yes | 9,242,986*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Viiv Hlthcare | APRETUDE | cabotegravir | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 215499-001 | Dec 20, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Viiv Hlthcare | APRETUDE | cabotegravir | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 215499-001 | Dec 20, 2021 | RX | Yes | Yes | 11,224,597 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Viiv Hlthcare
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Viiv Hlthcare | ZIAGEN | abacavir sulfate | TABLET;ORAL | 020977-001 | Dec 17, 1998 | 6,294,540*PED | ⤷ Try a Trial |
Viiv Hlthcare | TRIUMEQ | abacavir sulfate; dolutegravir sodium; lamivudine | TABLET;ORAL | 205551-001 | Aug 22, 2014 | 5,905,082*PED | ⤷ Try a Trial |
Viiv Hlthcare | RETROVIR | zidovudine | TABLET;ORAL | 020518-001 | Dec 19, 1995 | 4,818,538 | ⤷ Try a Trial |
Viiv Hlthcare | CABENUVA KIT | cabotegravir; rilpivirine | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212888-002 | Jan 21, 2021 | 6,838,464 | ⤷ Try a Trial |
Viiv Hlthcare | RETROVIR | zidovudine | TABLET;ORAL | 020518-001 | Dec 19, 1995 | 4,828,838 | ⤷ Try a Trial |
Viiv Hlthcare | RETROVIR | zidovudine | INJECTABLE;INJECTION | 019951-001 | Feb 2, 1990 | 4,828,838 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VIIV HLTHCARE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2007-10-16 |
➤ Subscribe | Tablets | 150 mg and 300 mg | ➤ Subscribe | 2011-08-08 |
➤ Subscribe | Oral Solution | 20 mg/ml | ➤ Subscribe | 2012-12-27 |
➤ Subscribe | Tablets | 150 mg/300 mg | ➤ Subscribe | 2007-06-26 |
➤ Subscribe | Tablets | 10 mg, 25 mg and 50 mg | ➤ Subscribe | 2017-08-14 |
➤ Subscribe | Tablets | 300 mg/150 mg/300 mg | ➤ Subscribe | 2011-03-22 |
➤ Subscribe | Oral Solution | 10 mg/mL | ➤ Subscribe | 2011-11-22 |
➤ Subscribe | Tablets | 300 mg | ➤ Subscribe | 2009-01-28 |
➤ Subscribe | Tablets | 700 mg | ➤ Subscribe | 2012-01-18 |
➤ Subscribe | Tablets | 600 mg/300 mg | ➤ Subscribe | 2007-09-27 |
➤ Subscribe | Tablets | 600 mg/50 mg/300 mg | ➤ Subscribe | 2017-08-14 |
International Patents for Viiv Hlthcare Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Brazil | PI0414027 | ⤷ Try a Trial |
Norway | 2017064 | ⤷ Try a Trial |
South Africa | 200701826 | ⤷ Try a Trial |
European Patent Office | 4316599 | ⤷ Try a Trial |
Luxembourg | 92853 | ⤷ Try a Trial |
Japan | 6268386 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Viiv Hlthcare Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1663240 | 92854 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, TEL QU'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, INCLUANT LE SEL CHLORHYDRATE DE RILPIVIRINE, ET TENOFOVIR, EN PARTICULIER LE FUMARATE DE TENOFOVIR DISOPROXIL |
1663240 | PA2016045 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: RILPIVIRINAS + TENOFOVIRO ALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/16/1112 20160621 |
2924034 | SPC/GB19/024 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: DORAVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH LAMIVUDINE AND TENOFOVIR DISOPROXIL; REGISTERED: UK EU/1/18/1333/001-002 20181122; UK PLGB 5305/0015 20181122 |
1663240 | 2015/052 | Ireland | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF RILPIVIRINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIDE SALT OF RILPIVIRINE, AND EMTRICITABINE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
1874117 | 300676 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: DOLUTEGRAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT DAARVAN, MET INBEGRIP VAN DOLUTEGRAVIR NATRIUM; REGISTRATION NO/DATE: EU/1/13/892 20140121 |
1663240 | 1590057-4 | Sweden | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF RILPIVIRINE, OR A PHARMACEUTICAL LY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIDE SALT OF RILPIVIRINE, AND TENOFOVIR DISOPROXIL, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE, AND EMTRICITABINE; REG. NO/DATE: EU/1/11/737 20111128 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.